BioNexus Gene Lab Operating Income

BioNexus Gene Lab (BGLC) currently reports a operating income of $-2.6M as of June 2026. That compares with $-3M in the prior-year period — up 14.3% year over year. Use the charts on this page to explore BioNexus Gene Lab's operating income history and peer comparisons.

BioNexus Gene Lab's operating income increased from $-3M to $-2.6M — a 14.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioNexus Gene Lab reported $-2.6M in operating income as of June 2026. That compares with $-3M in the prior-year period — up 14.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-2.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNexus Gene Lab, and consider following BGLC for alerts when major investors trade the stock.